Tag: nasdaq:ntla

March 20, 2020

The Rise of CRISPR Technology

CRISPR technology is a rapidly growing component of the genetics industry. Here's what investors need to know about its future...
February 27, 2020

Intellia Announces Q4 and Full-Year 2019 Financial Results

Intellia Therapeutics reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.
April 29, 2019

Intellia Therapeutics Presents New Data at Genetics Meeting

Intellia Therapeutics will showcase the first demonstration of targeted gene insertion with CRISPR/Cas9 in the liver of non-human primates during its...
August 24, 2018

Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution

Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, presented data from studies...